



PATENT
Attorney Docket No. 08201.0027-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BROWNING, et al.

Application No.: 10/077,137

Filed: February 15, 2002

For: BAFF RECEPTOR (BCMA), AN
IMMUNOREGULATORY AGENT

)
)
) Group Art Unit: 1645
)
) Examiner: Patricia Ann Duffy
)
)
) Confirmation No.: 2907
)

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**CERTIFICATE UNDER 37 CFR § 1.10 OF
MAILING BY "EXPRESS MAIL"**

EV 845470788 US

June 14, 2006

USPS Express Mail Label Number

Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By:

Katherine L. Staba
Katherine L. Staba

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 in the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent and published U.S. patent applications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 14, 2006

By: 
Nathaniel S. Edwards
Reg. No. 57,745

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	10/077,137
Filing Date	February 15, 2002
First Named Inventor	BROWNING et al.
Art Unit	1645
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	08201.0027-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-2006/0067933	03-30-2006	Gross et al.	
		US-6,774,106	08-10-2004	Theill et al.	
		US-2002/0086018	07-04-2002	Theill et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 01/087977	11-22-2001	Amgen Inc.		
		WO 01/087979	11-22-2001	Amgen Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Miller et al., "Genetic Studies of the <i>lac</i> Repressor," <i>J. Mol. Biol.</i> 131:191-222 (1979)	
		Moreland et al., "Etanercept Therapy in Rheumatoid Arthritis, A Randomized, Controlled Trial," <i>Ann. Intern. Med.</i> 130:478-486 (1999)	
		Smith et al., "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death," <i>Cell</i> 76:959-962 (1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label No. EY845470783US
Date of Deposit: June 14, 2006
By: Katherine L. Staba